China accounted for about 51 percent of counterfeit or substandard COVID-19-related products seized by U.S. customs officials from October 2019 to Sept. 30 last year, according to a newly-released report from the U.S. Customs and Border Protection (CBP).
Among the products seized by U.S. customs officials were over 12.7 million counterfeit masks, 177,356 COVID-19 test kits prohibited by the U.S. Food and Drug Administration (FDA), and 38,098 FDA-prohibited chloroquine tablets.
The effectiveness of the anti-malarial drug hydroxychloroquine and its closely-related chloroquine in treating symptoms of COVID-19, which is caused by the CCP virus (commonly known as the novel coronavirus), is of much debate.
The FDA initially issued an emergency use authorization for the two drugs, but later revoked the authorization in June last year, saying that they were “unlikely to be effective in treating COVID-19.”
However, there have been studies showing their effectiveness: one study showed hydroxychloroquine lowered the death rate of COVID-19 patients, while another study demonstrated a drug cocktail containing hydroxychloroquine could lower the hospitalization and death rate of patients infected by the virus. – READ MORE
Listen to the insightful Thomas Paine Podcast Below --